The Imfinzi (durvalumab) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of Imfinzi (durvalumab) has noticeably increased recent years. It is projected to rise from $2,701.22 million in 2024 to $3,013.33 million in 2025, with a Compound Annual Growth Rate (CAGR) of 11.6%.
By 2029, the Imfinzi (durvalumab) global market is projected to reach $4,143.36 million with a compound annual growth rate (CAGR) of 11.3%.
Download Your Free Sample of the 2025 Imfinzi (durvalumab) Market Report and Uncover Key Trends Now!The key drivers in the imfinzi durvalumab market are:
• The increase in cancer incidence due to aging population and lifestyle factors which leads to a greater demand for cancer treatments like Imfinzi (durvalumab).
• Increased use of Imfinzi (durvalumab) due to its ability to prevent cancer cells from evading detection by the immune system.
• Growth in the field of personalized medicine, leading to a demand for tailored treatments like Imfinzi (durvalumab).
• Advancements in genomic technologies and the growing availability of precision diagnostic tools that support the administration of personalized treatments using drugs like Imfinzi (durvalumab).
The imfinzi (durvalumab) market covered in this report is segmented –
1) By Type: 2.4mL Injection, 10mL Injection
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications
The key trends in the imfinzi durvalumab market are:
• Advancements in insulin formulation are emerging as a key trend.
• Development of biosimilar insulins is shaping the market landscape.
• Technological progress in insulin delivery systems is driving innovation.
• Collaboration between healthcare providers and pharmaceutical companies is becoming more prevalent.
Major players in the imfinzi durvalumab market are:
• AstraZeneca PLC
In 2024, North America was the leading region in the Imfinzi (durvalumab) market.